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The  aim  of this  study  was  to estimate  the  protective  effect  of  N-acetyl-l-cysteine  (NAC)  against  cisplatin-
induced  cardiotoxicity  under  conditions  of ischemic-reperfusion  injury.
Wistar  albino  rats  were  randomly  divided  into  three  groups  (n = 8):  control,  cisplatin  (5 mg/kg/w,  i.p.,
5  weeks)  and  cisplatin  +  NAC  group  (cisplatin  – 5 mg/kg/w,  i.p.  and  NAC  –  500  mg/kg/w,  i.p.,  5 weeks).
Isolated  hearts  were  perfused  according  to  the  modiﬁed  Langendorff  technique  at  constant  pressure
(70  cmH2O).  Following  cardiodynamic  parameters  were  measured:  maximum  rate  of left ventricular
pressure  development,  minimum  rate  of  left ventricular  pressure  development,  left ventricular  systolic
pressure  (SLVP),  left  ventricular  diastolic  pressure  and  heart  rate. The  ischemic  vasodilation  episodes  were
induced by the  complete  interruption  of  coronary  inﬂow  for 30,  60 and  120  s.  The  samples  of  the  coronary
venous  efﬂuent  (CVE)  were  continuously  collected  during  the  reperfusion  period  for determination  of
coronary  ﬂow  (CF)  rate  and  oxidative  stress  markers  (H2O2, O2−, NO2− and  thiobarbituric  acid  reactive
substances  – TBARS).
Cisplatin  reduced  CF,  heart  rate and  overﬂow  (total,  maximal  and  duration  of  overﬂow)  during  reperfu-
sion,  and  increased  SLVP  (under  basal  conditions  and  after  global  ischemias).  Cisplatin  increased  levels  of
H2O2 (under  basal  conditions),  O2− and  TBARS  (under  basal  conditions  and  after  ischemia),  but  decreased
−NO2 levels  (during  reperfusion)  in  CVE,  and  decreased  superoxide  dismutase  and  reduced  glutathione  in
serum. NAC  attenuated  cisplatin-induced  changes  of cardiodynamic  parameters  (except  CF  under  basal
conditions)  and oxidative  stress  parameters.
Those results  suggest  that NAC,  by  decreasing  oxidative  stress,  may  be  useful  in cardioprotection  during
cisplatin  therapy.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Since the accidental discovery four decades ago, cisplatin (cis-
ichlorodiammine-platinum(II), CDDP) remained one of the most
ommonly used chemotherapeutic drugs. The effect of this anti-
eoplastic agent has been demonstrated against various types
f tumors, such as solid tumors and hematological malignancies,
ncluding testicular, ovarian, bladder, head and neck, esophageal,
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214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).stomach and lung cancer, as well as lymphoma and osteosarcoma
[7]. Mechanism of cisplatin action is achieved by interaction with
DNA via formation of covalent adduct [56]. However, despite of its
beneﬁcial antitumor activity, cisplatin showed numerous adverse
effects and toxicities affecting gastrointestinal, renal, neurological
and hematological system, even when administered at standard
doses [62]. Although statistically classiﬁed as rare, cardiotoxicity is
one of the most serious side effects of cisplatin therapy described
in numerous studies.
This cardiotoxic manifestations of cisplatin include electro-
cardiographic changes, arrhythmias, cardiomyopathy, congestive
heart failure [70] and tromboembolic events [45]. Ischemia syn-
drome, palpitation and myocardial infarction can occur during
treatment with cisplatin, or even as long-term consequences [57].
Treatment with cisplatin can be also associated with occasional
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omplete atrioventricular block, hypotension [51] and recurrent
inus bradycardia [4].
It has been reported that cisplatin is able to generate reactive
xygen species (ROS), such as hydroxyl radical and superoxide
nion radical [67]. This very reactive oxygen species can cause
issue damage through reaction with biological macromolecules
lipids, proteins and nucleic acids) leading to the formation of oxi-
ized substances [31]. Nephrotoxicity induced by cisplatin, as one
f the most common side effect of cisplatin, is associated with an
ncrease of lipid peroxidation in the kidney tissue [6]. Also, some
tudies showed that cisplatin treatement may  induce decrease of
ntioxidants, such as superoxide dismutase (SOD) and reduced glu-
athione (GSH) in plasma [1] and this may  lead to failure of the
ntioxidative defense mechanisms against free radical-mediated
amage [66].
Cisplatin therapy is usually associated with oxidative stress that
as important role in cardiovascular toxicity after cisplatin treat-
ent [22]. Not surprisingly, there are numerous data suggesting
hat administration of various antioxidants may  be effective in
meliorating of cisplatin-induced toxicity in various tissues [34,47].
-Acetyl-l-cysteine (NAC) is a cysteine analog with free radi-
al scavenging activity, and is widely used as a chemoprotective
gent [39]. Numerous studies reported beneﬁcial effects of NAC on
isplatin-induced toxicity in various tissues and species, by means
f blocking apoptosis through the caspase-signaling pathway [69],
ncrease of intracellular GSH [58], scavenging ROS and via phospho-
xtracellular regulated kinase1/2 (ERK1/2) activation [72].
Aside of that, there are numerous reports concerning increase in
xygen free radicals during the reperfusion of ischemic cardiac tis-
ue [19,32]. Oxidative damage induced by increased ROS has been
onﬁrmed by increased levels of lipid peroxidation [25].
However, the interplay between two mechanisms that induce
xidative damage in the heart (of cisplatin and ischemic-
eperfusion origin) has not been evaluated yet. This study was
onducted in order to estimate the desirable protective effect of
AC (which has been proven to have antioxidant potentials) against
isplatin-induced cardiotoxicity under conditions of ischemic-
eperfusion injury.
. Material and methods
.1. Animals and treatment
Male Wistar albino rats (3 months old, 250–300 g body weight)
ere used in this study. Animals (obtained from Military Medical
cademy, Serbia) were maintained under well-controlled environ-
ental conditions of temperature (23 ± 1 ◦C) and light (12/12 h
ight/dark cycle), and had free access to food and water. Twenty four
ats were randomly divided into three groups (each group contain-
ng 8 rats): control, cisplatin and cisplatin + NAC group. Cisplatin
roup were injected (5 mg/kg/w, i.p.) for 5 weeks, while control
roup were injected by saline (i.p.), also for 5 weeks. Group cis-
latin + NAC received cisplatin (5 mg/kg/w, i.p., Merck, France) and
AC (500 mg/kg/w, i.p., Sigma–Aldrich, Germany). Applied doses
f cisplatin [60] and NAC [33] are comparable to patient treatment
egimens. All experiments were performed according to EU Direc-
ive for welfare of laboratory animals (86/609/EEC) and principles
f Good Laboratory Practice (GLP) approved by Ethical Committee
f the Faculty of Medical Sciences, University of Kragujevac, Serbia.
.2. Determination of coronary ﬂow rate and cardiodynamic
arameters
After short-term narcosis induced by intraperitoneal application
f ketamine (10 mg/kg) and xylazine (5 mg/kg), rats were sacri-orts 2 (2015) 996–1006 997
ﬁed by decapitation, and after prompt thoracotomy, hearts were
rapidly excised. According to the modiﬁed Langendorff technique
at constant pressure (70 cmH2O), hearts were perfused (Experime-
tria Ltd., Hungary) via aortic cannula with Krebs–Henseleit solution
(mM/l): NaCl 118, KCI 4.7, CaCl2·2H2O 2.5, MgSO4·7H2O 1.7,
NaHCO3 25, KH2PO4 1.2, glucose 11, and pyruvate 2. Solution was
gassed with 95% O2 plus 5% CO2, with pH maintained at 7.4 and
temperature of 37 ◦C. Cardiodynamic parameters were measured
by sensor (transducer BS4 73-0184, Experimetria Ltd., Hungary)
inserted in the left ventricle. The following parameters were reg-
istered: maximum rate of left ventricular pressure development
(dp/dt max), minimum rate of left ventricular pressure develop-
ment (dp/dt min), left ventricular systolic pressure (SLVP), left
ventricular diastolic pressure (DLVP) and heart rate (HR).
Following the equilibration period of 20 min  at the 70 cmH2O,
basal (preischemic) values of coronary ﬂow (also used for biochem-
ical assays) and cardiodynamic parameters were determined. The
ischemic vasodilation episodes (short-term global ischemia) were
induced by the interruption of coronary inﬂow (global ischemia)
for 30, 60 and 120 s, respectively. The intervals between the inter-
ruptions of the coronary inﬂow were approximately 15–20 min.
The following parameters for the coronary ﬂow during the reperfu-
sion were calculated: maximal (peak) overﬂow during reperfusion
(maximal value of coronary ﬂow rate during reperfusion compar-
ing to basal coronary ﬂow rate, given as percentage of increase),
total overﬂow during reperfusion (value of total coronary ﬂow rate
during reperfusion comparing to basal coronary ﬂow rate for the
same time period, given as percentage of increase), and total dura-
tion of overﬂow (total duration of increased coronary ﬂow above
the basal ﬂow rate during reperfusion, given in minutes). Values
of cardiodynamic parameters were determined at the end of each
minute through the reperfusion period.
2.3. Biochemical assays
The samples of the coronary venous efﬂuent (CVE) were col-
lected under basal conditions – before global ischemia, as well
as during the reperfusion periods and prepared for further anal-
ysis – the determination of biochemical markers of myocardial
injury (creatine kinase – CK and lactate dehydrogenase – LDH)
and oxidative stress markers (hydrogen peroxide H2O2; superoxide
anion radical – O2−; nitrite – NO2− and index of lipid peroxida-
tion, thiobarbituric acid reactive substances – TBARS) in CVE. For
determination of the levels for mentioned markers under basal
conditions we  collected the samples of CVE when it was consid-
ered as stable (with no change during 5 min). Levels of biochemical
markers of myocardial injury and oxidative stress markers after
global ischemia of different durations in CVE were estimated in
samples that were collected continuously during the whole reper-
fusion period (until the values of CF reached basal values). Samples
of adequate volumes of CVE were used for further analysis.
The samples for determination of biochemical markers of
myocardial injury (CK and LDH), as well as for determination of
antioxidants in blood (SOD and GSH) were collected immediately
after decapitation. Freshly separated sera for estimation of CK and
LDH levels in blood was obtained after centrifugation at 3000 rpm
for 10 min  and preserved at −20 ◦C until the determination of CK
and LDH levels. Isolated erythrocytes were washed three times with
three volumes of ice-cold 0.9 mM/l  NaCl, and then lysed with dH2O
(1:3, v/v) at 0 ◦C and preserved also at −20 ◦C until the determina-
tion of SOD and GSH levels in blood.2.3.1. Determination of CK and LDH
Levels of CK and LDH in CVE and serum were determined
spectrophotometrically using Roche Cobas system according to
manufacturer’s protocol. The values are presented as U/L.
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Table  1
Parameters of the coronary ﬂow under basal conditions and during reperfusion after global ischemia of different durations.
Parameter Group (treatment) Determination of coronary ﬂow
Basal conditions (before ischemia)
Coronary ﬂow (ml/min) Control 9.76 ± 0.70c,*
Cisplatin 6.76 ± 0.60a,*
Cisplatin + NAC 7.75 ± 0.26
During reperfusion
30 s ischemia 1 min  ischemia 2 min ischemia
Total  overﬂow after ischemia
of different duration
(% of increase comparing to basal CF values)
Control 22.35 ± 5.15 39.19 ± 10.34 72.43 ± 17.25
Cisplatin 7.38 ± 4.88a,* 12.00 ± 5.02a,* 8.61 ± 6.70a,*
Cisplatin + NAC 34.22 ± 2.86b,** 68.83 ± 6.34b,** 103.33 ± 13.07b,**
Maximal overﬂow after ischemia
of different duration
(% of increase comparing to basal CF values)
Control 17.30 ± 1.31c,* 24.59 ± 4.65 26.25 ± 4.48c,*
Cisplatin 5.64 ± 2.56a,* 9.03 ± 2.27a,* 5.41 ± 3.63a,*
Cisplatin + NAC 22.63 ± 1.69b,** 36.76 ± 0.87b,** 42.55 ± 1.43b,**
Duration of overﬂow after ischemia
of different duration (in minutes)
Control 2.00 ± 0.32 2.60 ± 0.60c,* 4.00 ± 0.63
Cisplatin 0.80 ± 0.37a,* 1.80 ± 0.90 1.00 ± 0.71a,*
Cisplatin + NAC 2.50 ± 0.29b,* 4.50 ± 0.29b,** 4.75 ± 0.25b,*
Values are expressed as mean ± S.E.M. for eight animals.
a Control vs. cisplatin.
b Cisplatin vs. cisplatin + NAC.
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.3.2. Determination of H2O2
The measurement of H2O2 is based on the oxidation of Phenol
ed by H2O2 in a reaction catalyzed by horseradish peroxidase –
RPO [55]. A volume of 200 l of perfusate was precipitated with
00 l of fresh Phenol Red solution, along with 10 l of 1:20HRPO
made ex tempore). An adequate volume of Krebs–Henseleit solu-
ion was used for a blank probe (instead of coronary venous
fﬂuent).
.3.3. Determination of O2−
The level of the O2− was measured by Nitro Blue Tetra-
olium reaction in TRIS-buffer with coronary venous efﬂuent.
rebs–Henseleit solution was used as a blank probe [10].
.3.4. Determination of NO2−
Nitrite was determined and used as an index of nitrite oxide pro-
uction by the spectrophotometric method using Gries’s reagent.
 total of 0.5 ml  of perfusate was precipitated with 200 l of
0% sulphosalicylic acid, vortexed for 30 min, and centrifuged at
000 × g. Equal volumes of the supernatant and Gries’s reagent,
ontaining 1% sulphanilamide in 5% phosphoric acid/0.1% naphtha-
ene ethylenediamine–dihydrochloride, were added, incubated for
0 min  in the dark. The nitrite levels were calculated using sodium
itrite as the standard [29].
.3.5. Determination of TBARS
For estimation of the degree of lipid peroxidation we mea-
ured TBARS using 1% thiobarbituric acid in 0.05 NaOH incubated
ith the coronary efﬂuent at 100 ◦C for 15 min. As a blank probe
rebs–Henseleit solution was used [49].
.3.6. Determination of SOD
SOD activity was determined by the epinephrine method [44]
n which 100 l lysate and 1 ml  carbonate buffer were mixed, and
hen 100 l epinephrine was added. The activity of SOD in red blood
ells (RBCs) is presented in units per gram of hemoglobin × 103 (U/g
b × 103).
.3.7. Determination of GSH
Level of GSH was determined according to Beutler [12] based on
SH oxidation via 5.5 dithiobis-6.2-nitrobenzoic acid (DTNB). GSH
xtract was obtained by combining 0.1 ml  0.1% EDTA, 50 l erythro-
yte lysate and 750 l precipitation solution. After vortexing andextraction on cold ice for 15 min, centrifugation at 4000 rpm was
performed for 10 min. 300 l, 750 l Na2HPO4 and 100 l DTNB
was pipetted into test tubes. As a blank probe, distilled water was
used. Concentration and the amount of GSH were determined on
the basis of a standard curve for each assay. For standard curve
construction, standard stock-solution of GSH at a concentration
1.5 mM/l  was used. The concentration is expressed as nanomoles
per millilitre of erythrocytes.
All markers of oxidative stress (H2O2, O2−, NO2− and TBARS)
as well as the levels of antioxidants (SOD and GSH) were measured
spectrophotometrically (Shimadzu UV 1800, Japan) at 610, 530, 543
and 530 nm,  respectively, for markers of oxidative stress, and 470
and 412 nm,  for SOD and GSH, respectively.
2.4. Statistical analysis
All values were expressed as mean ± S.E.M. Statistical analy-
sis was  performed by IBM SPSS Statistics version 20. Variables
were checked for normal distributions of the data with the
Shapiro–Wilks test. Comparison of means was  done by the Stu-
dent’s t-test (One way ANOVA) and the Kruskal–Wallis test. Data
were considered statistically signiﬁcant at p value <0.05.
3. Results
3.1. Changes of coronary ﬂow
Basal rates of coronary ﬂow (before ischemia) observed in
cisplatin group were signiﬁcantly lower than in control group. Cis-
platin plus NAC group increased basal coronary ﬂow comparing to
cisplatin group, but it was still lower comparing to control group
(Table 1).
The total overﬂow after global ischemia gradually increased in
control group following increase in duration of ischemia. In cis-
platin group, total overﬂow remained the same values, signiﬁcantly
lower comparing to control, with no change after the elongation
of global ischemia. NAC administration along with cisplatin sig-
niﬁcantly increased total overﬂow during reperfusion for all three
durations of global ischemia comparing to cisplatin group (Table 1).Maximal (peak) ﬂow during reperfusion progressively enhanced
following the increase in duration of global ischemia. Peak ﬂow in
cisplatin group was almost constant, at signiﬁcantly lower levels,
for all three durations of ischemia comparing to control group. Cis-
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all durations, while NAC supplementation failed to decrease highig. 1. Overﬂow after global ischemia of 30 (A), 60 (B) and 120 (C) seconds.
alues are expressed as mean ± S.E.M. for eight animals (*p < 0.05, **p < 0.01). a –
ontrol vs. cisplatin; b – cisplatin vs. cisplatin + NAC; c – control vs. cisplatin + NAC
latin plus NAC group showed signiﬁcant increase in maximal ﬂow
ollowing global ischemia of all three different durations comparing
o the cisplatin group (Table 1). This increase in maximal ﬂow dur-
ng reperfusion was even signiﬁcantly higher comparing to control
roup (for global ischemia of 30 s and 2 min).
The total duration of overﬂow observed in control group showed
rogressive increase depending on the duration of global ischemia.
otal duration of overﬂow during reperfusion was signiﬁcantly
ower comparing to control group, maintaining the same values
egardless of the ischemia duration. Simultaneous administration
f NAC with cisplatin signiﬁcantly increased total duration of over-
ow during reperfusion comparing to the cisplatin group for all
hree different durations of global ischemia. This effect of NAC on
uration of overﬂow was above the values in the control group after
lobal ischemia of 1 min  (Table 1).
Overﬂow following global ischemia observed in the cisplatin
roup was signiﬁcantly lower comparing to control by means of
ll evaluated parameters (i.e., total and maximal overﬂow, dura-
ion of overﬂow) throughout the whole reperfusion period (Fig. 1).
ecrease of coronary overﬂow in cisplatin group was manifested
fter global ischemia of all three durations. NAC administration
long with cisplatin signiﬁcantly increased coronary overﬂow afterorts 2 (2015) 996–1006 999
global ischemia comparing to cisplatin group, and even comparing
to control group (for peak overﬂow and for the total duration of
overﬂow).
3.2. Changes of cardiodynamic parameters
SLVP before ischemia was  signiﬁcantly higher in cisplatin group
comparing to control group. Simultaneous administration of NAC
with cisplatin signiﬁcantly reduced basal SLVP (before ischemia)
comparing to cisplatin group, backing SLVP almost to control val-
ues (Fig. 2). Values of SLVP did not signiﬁcantly change during
reperfusion period in all three groups and for all three durations
of global ischemia, comparing to their basal values, maintaining
the differences observed for basal values in the groups. There
was no signiﬁcant difference in basal DLVP between control, cis-
platin and cisplatin with NAC group (5.08 ± 0.84, 4.92 ± 0.20 and
4.68 ± 0.65 mmHg, respectively). Also, DLVP did not change fol-
lowing global ischemia of different durations in all three groups
preserving the values similar to basal.
Left ventricle contractility (dp/dt max) before global ischemia
was signiﬁcantly higher in cisplatin group comparing to control
group, while NAC supplementation attenuated this cisplatin effect
on basal dp/dt max  (Fig. 3, top). Contractility signiﬁcantly increased
during reperfusion in control group comparing to the basal val-
ues following the enhancing of ischemia duration. This was not
observed in cisplatin and cisplatin plus NAC groups (Fig. 3, top).
There was no signiﬁcant difference in left ventricle relaxation
(dp/dt min) between control, cisplatin and cisplatin plus NAC group
(Fig. 3, bellow). Also, there was  no change in relaxation rate dur-
ing reperfusion comparing to basal (preishemic) values in all three
groups for global ischemia of different durations.
Heart rate in cisplatin group was signiﬁcantly lower compar-
ing to control group. Simultaneous administration of NAC with
cisplatin signiﬁcantly increased HR comparing to cisplatin group,
returning HR to the values similar to control (Fig. 4). Heart
rate did not change following global ischemia of different dura-
tions in all experimental groups preserving the values similar to
basal.
3.3. Changes of markers of myocardial injury
The levels of CK in CVE under basal conditions in cisplatin group
were signiﬁcantly higher comparing to control (Table 2). NAC appli-
cation reduced CK levels in CVE under basal conditions, but they
were still above the control values. Also, CK levels in CVE following
global ischemia of different durations were signiﬁcantly increased
in cisplatin group for all durations of ischemia comparing to control
group. NAC supplementation along with cisplatin therapy abol-
ished the increase in CK observed in cisplatin group. There were
no signiﬁcant changes in CK levels during reperfusion after global
ischemia of any duration in cisplatin and cisplatin + NAC groups
comparing to control values. Serum levels of CK in cisplatin group
were also signiﬁcantly higher comparing to control group. NAC
supplementation reduced CK levels comparing to cisplatin group
(not signiﬁcantly), although the CK levels remained signiﬁcantly
increased comparing to control group (Table 2).
LDH levels in CVE in cisplatin group were signiﬁcantly higher
when compared to control under basal conditions (Table 2). NAC
administration along with cisplatin did not decrease LDH levels
observed in cisplatin group, remaining signiﬁcantly higher levels
comparing to control. Cisplatin induced increase in LDH levels com-
paring to control group was  also observed after global ischemia oflevels of LDH following cisplatin application comparing to con-
trol group. LDH concentrations during reperfusion following global
ischemia of all durations showed no change comparing to preis-
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Fig. 2. Changes of SLVP before and after global ischemia of different durations. Values are expressed as mean ± S.E.M. for eight animals (*p < 0.05).
Fig. 3. Changes of dp/dt max  and dp/dt min  before and after global ischemia of different durations.
Values are expressed as mean ± S.E.M. for eight animals (*p < 0.05, **p < 0.01).
ons. 
c
5
t
t
nFig. 4. Changes of heart rate before and after global ischemia of different durati
hemic conditions in al groups. LDH concentrations in serum after
 weeks of cisplatin therapy were signiﬁcantly higher comparing
o control group. NAC administration along with chronic cisplatin
herapy signiﬁcantly decreased LDH levels, but they remained sig-
iﬁcantly above the control values (Table 2).Values are expressed as mean ± S.E.M. for eight animals (*p < 0.05, **p  < 0.01).
3.4. Changes of oxidative stress parametersThe levels of H2O2 under basal conditions (preischemic values)
were signiﬁcantly higher in cisplatin group comparing to control
group (Fig. 5A). However, there was no signiﬁcant difference in
H2O2 concentration after global ischemia (of any duration) in cis-
G. Rosic et al. / Toxicology Reports 2 (2015) 996–1006 1001
Table  2
Levels of creatin kinase (CK) and lactate dehydrogenase (LDH) in serum and coronary venous efﬂuent (CVE) under basal conditions and during reperfusion after global
ischemia of different durations.
Group (treatment) Basal conditions (U/L in CVE) 30 s ischemia (U/L in CVE) 1 min  ischemia (U/L in CVE) 2 min  ischemia (U/L in CVE) Serum (U/L)
CK
Control 7.00 ± 0.96c,* 6.33 ± 0.67 6.66 ± 0.41 7.00 ± 0.71 198 ± 21.55c,**
Cisplatin 12.20 ± 2.10a,* 13.20 ± 2.92a,* 11.70 ± 2.25a,* 11.33 ± 2.27a,* 374.4 ± 9.72a,**
Cisplatin + NAC 10.94 ± 1.39 9.33 ± 2.53 9.33 ± 2.48 10.00 ± 2.63 337 ± 25.70
LDH
Control  2.33 ± 0.41c,* 2.00 ± 0.27 3.33 ± 0.31 2.00 ± 0.27 223.00 ± 15.92c,*
Cisplatin 4.00 ± 0.53a,* 4.50 ± 1.01a,* 4.17 ± 0.23a,* 3.83 ± 0.80a,* 491.00 ± 60.68a,**
Cisplatin + NAC 3.97 ± 0.64 3.00 ± 0.53 3.67 ± 0.82 3.33 ± 1.11 330.50 ± 17.12b,*
Values are expressed as mean ± S.E.M. for eight animals.
a Control vs. cisplatin.
b Cisplatin vs. cisplatin + NAC.
c Control vs. cisplatin + NAC.
* p < 0.05.
** p < 0.01.
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alues  are expressed as mean ± S.E.M. for eight animals (*p  < 0.05, **p < 0.01).
latin group comparing to control. Simultaneous administration
f NAC along with cisplatin signiﬁcantly reduced basal concentra-
ions of H2O2 comparing to cisplatin group, as well as after global
schemia of all durations. Even with no difference under basal con-
itions, decrease in H2O2 in cisplatin plus NAC group was  also
igniﬁcant following global ischemia (of all durations) comparing
o control group. Levels of H2O2 did not signiﬁcantly change fol-
owing global ischemia of different durations (comparing to basal
alues) in all three groups preserving the values similar to differ-
nces observed under basal conditions.In contrary, O2− release in cisplatin group was  not signiﬁcantly
igher comparing to preischemic values in control group. Concen-
ration of O2− signiﬁcantly increased after global ischemia of 30 s
nd maintained signiﬁcantly higher levels with increasing durationoronary venous efﬂuent before and after global ischemia of different durations.
of global ischemia comparing to control group (Fig. 5B). Simul-
taneous administration of NAC along with cisplatin signiﬁcantly
decreased concentration of O2− under basal conditions, as well
as after global ischemia of all durations, comparing to cisplatin
group. Also, decrease in O2− release in cisplatin plus NAC group was
signiﬁcant comparing to control group. Released O2− did not sig-
niﬁcantly change following global ischemia of different durations
(comparing to basal values) in control and cisplatin plus NAC group,
maintaining the values similar to observed under basal conditions.
However, even with no signiﬁcant change between two consecu-
tive durations of global ischemia, O2− concentrations in cisplatin
group gradually increased comparing to basal values (basal vs. 60 s
and 120 s ischemia – 1.91 ± 0.22 vs. 2.61 ± 0.19 and 2.97 ± 0.18; p
< 0.05 and p < 0.01, respectively).
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Table  3
Serum levels of superoxide dismutase (SOD) and reduced glutathione (GSH).
Group (treatment) SOD (U/g Hgb × 103) GSH (nM/ml erythrocytes)
Control 6.00 ± 0.58c,* 1131 ± 31.45
Cisplatin 2.40 ± 0.33a,** 661.67 ± 35.16a,**
Cisplatin + NAC 4.00 ± 0.58b,* 1014.17 ± 65.45b,**
Values are expressed as mean ± S.E.M. for eight animals.
a Control vs. cisplatin.
b Cisplatin vs. cisplatin + NAC.
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fControl vs. cisplatin + NAC.
* p < 0.05.
** p < 0.01.
NO2− release in cisplatin group was not signiﬁcantly lower
omparing to control group before ischemia. However, signiﬁcant
uppression of NO2− release was observed in cisplatin group dur-
ng reperfusion after all three durations of global ischemia. NAC
upplementation increased NO2− concentration comparing to cis-
latin group under basal conditions, as well as after global ischemia
all three durations). Administration of NAC with cisplatin resulted
n increased levels of NO2− in preischemic period with no change
uring reperfusion period comparing to control group after all three
urations of global ischemia (Fig. 5C).
Preishemic TBARS concentration was signiﬁcantly increased in
isplatin group comparing to control group (Fig. 5D). Higher lev-
ls of TBARS in cisplatin group comparing to control were also
bserved during reperfusion following global ischemia (all three
urations). Simultaneous administration of NAC along with cis-
latin signiﬁcantly reduced TBARS concentration comparing to
isplatin group under basal conditions, as well as after all three
urations of global ischemia. Still, TBARS levels in cisplatin plus NAC
roup remained above the control values (not signiﬁcant) under
oth pre and after ischemic conditions (all three durations of global
schemia).
Blood levels of SOD and GSH observed in cisplatin group were
igniﬁcantly lower comparing to control group (Table 3). Simulta-
eous administration of NAC with cisplatin signiﬁcantly increased
OD and GSH when compare to cisplain group. SOD activity fol-
owing NAC application along with cisplatin therapy remained
igniﬁcantly lower comparing to control group (Table 3).
. Discussion
Numerous cardiotoxic effects are reported to be accompanied
ith chronic cisplatin therapy, such as various types of arrhyth-
ia, ischemic heart disease and heart failure [23]. Many of cardiac
and other) adverse effects of cisplatin alone, and in combination
ith some other chemotherapeutic agents, are connected with
isplatin-induced oxidative damage [17]. The aim of this study was
o evaluate the effects of chronic cisplatin treatment on coronary
ow and cardiodynamic parameters of the isolated rat heart after
lobal ischemia. The protocol for cisplatin application was cho-
en in order to mimic  cyclic administration of cisplatin in various
hemotherapeutical protocols in humans [16]. Also, we  evaluated
he effects of NAC, as an antioxidant agent, on cisplatin-induced
hanges in rat heart under ischemic conditions. Applied NAC dose
as been reported to have cardioprotective effects (by reducing
xidative damage) in rat heart [30].
Five weeks of cisplatin treatment (5 mg/kg/week) resulted in
ecreased basal coronary ﬂow (app. 30%). Although, reduction of
oronary ﬂow was reported after acute cisplatin application in iso-
ated perfused rat heart [43], the effect of chronic cisplatin therapy
n overall coronary ﬂow was not previously observed. Due to lack of
ata obtained on animal models concerning this cardiotoxic effect
f cisplatin, we can only compare our results with some case reports
or the patients undergoing cisplatin therapy. Observed reductionorts 2 (2015) 996–1006
of coronary ﬂow in our study is in line with some manifestations of
ischemic heart disease accompanied with cisplatin therapy, such as
coronary syndrome [52], unstable angina [36], and acute myocar-
dial infarction [27]. Causal connection between cisplatin treatment
and decrease in coronary ﬂow could be found in the vasospasm [35]
and alterations of endothelial cells integrity and increase of sys-
temic procoagulant factors [15]. NAC supplementation along with
cisplatin therapy increased basal coronary ﬂow comparing to cis-
platin alone (10–15%, not signiﬁcant), but it was  still below the
control values (Table 1). Observed increase of coronary ﬂow after
NAC treatment leads to the conclusion that at least part of adverse
effect of cisplatin on coronary ﬂow may  be attributed to increased
oxidative damage. It seems that cisplatin treatment leads to both
decrease of coronary ﬂow (under basal conditions) and coronary
reactivity. Those adverse effects of cisplatin were attenuated with
NAC. However, NAC did not produce signiﬁcant change (increase)
of CF under basal conditions while that beneﬁcial effect of NAC on
CF was  more pronounced during reperfusion. Such difference could
be explained by the fact that ischemic events resulted in increased
production of ROS, and that enabled better insight in beneﬁcial
effect of NAC in coronary circulation. The possible mechanism of
NAC antioxidative effect [8] could be found in increased GSH levels
caused by NAC (Table 3). This is in accordance with literature data
that report beneﬁcial effect of different antioxidants by means of
the reduction of the oxidative stress induced by various chemother-
apeutic agents. Cisplatin-induced oxidative damage was  reduced
with ginger extract [9], dl-alpha-lipoic acid [34], garlic extract [47]
and ellagic acid [71].
All parameters deﬁned in order to quantify coronary ﬂow dur-
ing reperfusion following global ischemia of different durations
had been evidently changed after chronic treatment with cisplatin.
Total overﬂow and peak (maximal) overﬂow, as well as the dura-
tion of overﬂow, after cisplatin treatment were 3–10 fold lower
comparing to control. Also, there was  no progressive increase of
those parameters following the increase of the global ischemia
duration that was  observed in control group (Table 1). Adverse
cisplatin effect on coronary ﬂow during reperfusion was  even
more pronounced than the effect on the coronary ﬂow under
basal conditions suggesting devastating inﬂuence of chronic cis-
platin treatment on the coronary vessels reactivity. This cardiotoxic
effect of cisplatin was  clearly observed through the whole reper-
fusion (Fig. 1). However, application of NAC along with cisplatin
completely restored reactivity of coronary vessels. Even more,
parameters of coronary ﬂow during reperfusion following global
ischemia of different durations after NAC treatment were above
the values obtained in control group through the whole reperfu-
sion period (Fig. 1). This obvious cardioprotective effect of NAC on
cisplatin-induced decrease of coronary reactivity after ischemia is
in line with previously reported beneﬁcial effects of NAC in myocar-
dial ischemia [37,50,61].
Chronic cisplatin treatment increased SLVP and left ventricle
contractility (30% and 20%, respectively) under basal conditions,
i.e., before global ischemia, with no change in DLVP and left
ventricle relaxation (Figs. 2 and 3). Except the left ventricle con-
tractility in control group (gradual increase along the elongation of
global ischemia), none of those left ventricular function parame-
ters changed during reperfusion period following global ischemia
(for all three durations of ischemia) suggesting that postischemic
events, under this experimental protocol, did not affect left ventric-
ular function in all experimental groups. Previous studies reported
cisplatin-induced reduction of left ventricle function in mice [40]
and in humans [3]. Those results are not in line with the results of
our study. The opposite effects of chronic cisplatin treatment on
left ventricular function parameters may  be explained by species
differences, as well as by different protocols (and doses) for cis-
platin therapy. Our previous results show similar effects of acute
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isplatin treatment (slight increase) on left ventricle [43]. Cisplatin-
nduced increase of SLVP and left ventricle contractility may  be
ausally connected to increased systolic arterial pressure after long-
erm cisplatin therapy accompanied with renal failure [42] and
ncreased peripheral vascular resistance due to vasospasm [35].
he both mentioned possible reasons for induced increase of left
entricle function are closely related to increased oxidative dam-
ge after cisplatin therapy [38,63]. Therefore, it is not surprising
hat NAC supplementation along with cisplatin therapy reduced
isplatin-induced increase of SLVP (app. 25%) and left ventricle
ontractility (app. 20%, not signiﬁcant). However, it still remains
nclear whether this cardioprotective effect of NAC was predom-
nantly achieved via direct action on cardiac muscle or due to
ecreased afterload.
Negative chronotropic effect of cisplatin was  clearly observed
nder basal (preischemic) conditions, as well during the reperfu-
ion period for all durations of global ischemia. Possible explanation
or this cardiotoxic effect of cisplatin may  be found in evidence for
he deposition of cisplatin in the region of sinoatrial node [59]. It has
een reported that cisplatin-induced bradicardia may  be related to
ecurrent AV block [51] Also, negative chronotropic effect of cis-
latin was observed after acute cisplatin application in isolated
erfused rat heart [43]. However, NAC application in combina-
ion with cisplatin completely reversed cisplatin-induced negative
hronotropic effect (Fig. 4). Cardioprotective effect of NAC on HR
uggests that cisplatin-induced oxidative damage may  be involved
n accumulation of cisplatin in sinoatrial node and/or in the distur-
ances of AV conduction. Furthermore, it should be underlined that
egative chronotropic effect of cisplatin, simultaneously accompa-
ied with the marked reduction of coronary ﬂow, may  be the cause
f compensatory mechanism within the heart that can rely only
n positive inotropic response (Figs. 2 and 3) in order to maintain
equired (critical) coronary ﬂow.
It has been previously reported that chronic cisplatin treatment
ncreased the levels of biochemical markers of myocardial injury
n humans [18]. Results of this study concerning the increased
evels CK and LDH after cisplatin therapy in serum are in line pre-
ious observations for cisplatin induced elevation of CK and LDH
n rats [64]. Elevated levels of those markers of myocardial injury
emained above the control values after NAC application along with
isplatin treatment (Table 2). However, NAC lowered CK (not sig-
iﬁcantly) and LDH (signiﬁcantly) levels comparing to cisplatin
herapy group alone. Beneﬁcial effect of various antioxidants, such
s dl-alpha-lipoic acid and silymarin [22] and ginger extract [9],
n CK and LDH levels in blood following cisplatin therapy have
een conﬁrmed, suggesting that cisplatin-induced oxidative dam-
ge may  lead to disruption of cell membranes resulting in release
f intracellular proteins, such as CK, LDH and troponin T [18].
Although, there is no data concerning the effects of cisplatin on
yocardial injury after global (and any other) ischemia, it was  hard
o believe that such pronounced disturbance of oxidative balance
nd coronary homeostasis would not affect the reactivity of coro-
ary vessels during reperfusion. Indeed, CK and LDH levels in CVE
ere signiﬁcantly higher after chronic cisplatin treatment under
asal conditions (values before global ischemia), and remained
igher during reperfusion following global ischemia of all dura-
ions. NAC supplementation along with cisplatin therapy failed to
educe CK and LDH levels under basal conditions, but it resulted
n abolishing of cisplatin-induced increase of CK and LDH levels
uring reperfusion following ischemia of all durations (Table 2).
ifferences in CK and LDH levels observed between the effects of
AC under basal (preischemic) conditions and after ischemia could
e explained by signiﬁcant increase of CF during reperfusion (Fig. 1)
eading to better washout and dilution of released of intracellular
roteins. Beneﬁcial effects of NAC on ischemic injury of the human
nd rabbit hearts have been previously reported [54]. Also, theorts 2 (2015) 996–1006 1003
other antioxidants (lavender ﬂower and tribulosin) showed cardio-
protective effects by means of reduced levels of myocardial injury
markers in CVE during ischemia-reperfusion injury [65,73], respec-
tively). Furthermore, it is obvious that levels of CK and LDH did
not change following global ischemia of any durations comparing
to control values. This conﬁrms that applied durations of ischemia
did not caused further lesions of myocardium, but those short-term
episodes of global ischemia were sufﬁcient for testing the changes
of coronary vessels reactivity between the groups.
Recent studies have demonstrated that cisplatin application
interrupts redox homeostasis by stimulation of ROS overproduc-
tion [13] and reduction of antioxidative enzymes activity [22],
which strongly encourage the using of free radical scavengers
and antioxidants, such as NAC and others, to counteract cisplatin-
induced toxicities [20,53]. However, the vast majority of these
ﬁndings come from experimental and clinical investigations on
kidneys (probably due to evident nephrotoxity of cisplatin), while
data related to effects of cisplatin on the cardiac muscle are still
inconsistent and insufﬁcient.
Polyunsaturated fatty acids of membrane lipids are highly sus-
ceptible to peroxidation enhanced by cisplatin activity [34]. In
present study we  used TBARS levels, as marker of lipid peroxida-
tion, and found increased basal TBARS concentration in cisplatin
group comparing to control, which is in accordance with previ-
ous results on similar experimental protocols [2]. The increase in
TBARS levels after cisplatin treatment was also observed follow-
ing all three durations of ischemia. Previous studies have shown
that reperfusion-induced increasing of free radicals was paralleled
with elevated rates of lipid peroxidation [14]. However, elonga-
tion of ischemia did not produce any difference in TBARS levels
in both control and cisplatin group, suggesting that the most
of differences in lipid peroxidation for this experimental proto-
col was previously achieved (during chronic cisplatin treatment)
with no signiﬁcant changes regarding acute ischemia/reperfusion
episodes. Decrease in TBARS concentrations following NAC treat-
ment, comparing to cisplatin group, was  clearly observed under
basal conditions, as well as after global ischemia of all three dura-
tions (Fig. 5D). This beneﬁcial effect of NAC may  be achieved by
abolishing of cisplatin-induced oxidative damage, due to diminish-
ing nuclear factor (NF)-B signaling pathway [68], which has been
noted to cause cell apoptosis.
NO, another ROS whose mechanism of action is widely investi-
gated, can inhibit lipid peroxidation, and also act as an antioxidant
agent regarding the cell protection from oxidative stress [21]. Thus
NO inﬂuences the regulation of many biological responses such
as induction and activation of genes, inhibition of thrombocyte
aggregation, cytostasis, apoptosis, neurotransmission, stimulation
of immune response, and relaxation of vascular smooth muscles
[41]. When NO and O2− are excessively produced, they can inter-
act and generate a highly toxic peroxynitrite (ONOO−) and thus
reduces NO concentration [26]. In this investigation, NO concen-
trations were estimated by means of NO2− levels in coronary
venous efﬂuent. Even cisplatin had no effect on NO2− produc-
tion under basal conditions, ischemia-induced response in NO2−
release during reperfusion showed signiﬁcant decrease after cis-
platin therapy (Fig. 5C). Cisplatin-induced suppression of NO2−
production was  observed after all three durations of ischemia com-
paring to control. Possible explanation for decreased NO2− release
after ischemia could be found on the fact that during reperfusion
excessive amount of O2− can be produced and thus reduce the func-
tion of nitric oxide synthases [24], shortening the half-life of NO
and decreasing its bioavailability. However, administration of NAC
along with cisplatin resulted in signiﬁcant increase in NO2− levels
both under basal conditions and during reperfusion periods follow-
ing ischemia of all durations. Furthermore, NAC increased NO2−
production even above the levels achieved in control group under
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asal conditions. This certain cardioprotective effect of NAC could
e also attributed to increased nitric oxide synthases activity [24].
Although with no effect on O2− release under basal condi-
ions, cisplatin-induced increase in O2− levels after global ischemia
f 30 s (maintaining higher levels following increase in duration
f global ischemia) comparing to control group. This is in line
ith the ﬁndings observed in human population [5]. Nevertheless,
AC administration attenuates this effect of cisplatin by reduc-
ng O2− levels. Similar results have been reported on cell cultures
f the infracted heart [5], conﬁrming antioxidative potentials of
his agent. Moreover, suppression of O2− production after NAC
upplementation was signiﬁcant even comparing to control group
Fig. 5B).
In contrary, cisplatin induced rise in basal H2O2 levels, but after
lobal ischemia (of any duration) H2O2 lowered, resuming almost
he same values comparing to control group. Observed increase
n basal production of H2O2 after cisplatin administration is in
ccordance with literature data, conﬁrming that cisplatin-induced
xidative stress may  be considered as the major mechanism of
ell apoptosis [11]. The lack of further post-ischemic increase in
2O2 levels in cisplatin group may  be attributed to limited cell
apacity to generate this ROS during observed period of reperfu-
ion above already high levels achieved under basal conditions.
eduction of both basal and post-ischemic H2O2 concentrations
fter NAC administration conﬁrmed its ability to reduce H2O2 pro-
uction (Fig. 5A). This result is in line with recent report for muscle
ell cultures [46].
Furthermore, we noticed interesting dynamic for some parame-
ers of antioxidative defense system, by means of alterations of SOD
nd GSH levels (Table 3). Chronic cisplatin treatment performed
n this study signiﬁcantly decreased blood levels of GSH and SOD
for 40% and 60%, respectively) comparing to control group. Our
esults are in accordance with previously described effects of cis-
latin (and its analogs) on isolated human breast cancer cells [28].
esults of that study showed that cisplatin treatment reduced the
ctivity of antioxidant enzymes such as glutathione peroxidase and
lutathione reductase and also decreased levels of small-molecule
ntioxidants such as GSH, vitamins E and A. Moreover, decreased
evels of GSH, as well as the inhibition of the catalase and SOD activ-
ty in rats treated with cisplatin were recently conﬁrmed [1]. NAC
upplementation along with cisplatin treatment in our protocol
esulted in increased intracellular GSH and SOD levels compar-
ng to cisplatin group. However, SOD levels remained signiﬁcantly
ower comparing to control group. Those results are in line with
he data concerning beneﬁcial effects of antioxidants (quercetin)
n ciplatin-induced nephrotoxicity in rats [1]. Furthermore, GSH,
s well as superoxide dismutase and dimethylthiourea, has been
hown to reduce the degree of renal failure and tubular cell damage
hen administered simultaneously with cisplatin in rats [48,74].
ossible mechanism which is included in positive effects of NAC
n antioxidative enzymes on molecular level is still unknown. Yet,
t has been proposed that the beneﬁcial effects of NAC, as a cell-
ermeable precursor of GSH, may  be related to either increase of
ntracellular GSH, or the ability to sustain high intracellular GSH
evels [58]. Moreover, it has been reported that NAC exerts its
rotective effect in part directly by scavenging ROS and in part
ia phospho-extracellular regulated kinase1/2 (ERK1/2) activation
72], suggesting that cysteinyl thiol (of NAC) provided its antioxi-
ant properties.
In conclusion, we can summarize that chronic cisplatin treat-
ent produced numerous adverse effects in isolated rat heart
reduction of coronary ﬂow, heart rate, etc.). Those carditoxic
ffects of cisplatin even worsened after the episodes of short-term
schemia. Also, ﬁndings of present study regarding oxidative stress
arkers suggest that cisplatin-induced cardiotoxity may  be accom-
lished via induction of oxidative stress and that cardiac effect of
[orts 2 (2015) 996–1006
cisplatin under ischemia/reperfusion conditions depend on spe-
ciﬁc type of ROS. NAC has been showed to possess a wide range of
cardioprotective efﬁciency, scavenging all estimated pro-oxidative
markers (and enhancing antioxidant capacity of cardiomyocytes),
in both pre- and post-ishemic periods, leading to restoration of
cardiodynamic parameters. This data could have potential clinical
importance pointing NAC as a possible adjuvant during cisplatin
therapeutic algorithms.
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